Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilfrid Richer

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|October 27, 2018
IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During <i>Trypanosoma cruzi</i> InfectionJimena Tosello Boari, Cintia L Araujo Furlan, Facundo Fiocca Vernengo, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Journal for Immunotherapy of Cancer|November 19, 2024
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustionAnais Debesset, Caroline Pilon, Sylvain Meunier, et al.
Plos Biology|June 18, 2026
Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancerDario Pasquale Anobile, Layla Barbar, Emile Maucotel, et al.
Oncoimmunology|May 12, 2025
CD8<sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevanceCarolina Abrate, Fernando P Canale, Sabrina N Bossio, et al.
Nature Communications|January 29, 2016
The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivationZhi-Yan Han, Wilfrid Richer, Paul Fréneaux, et al.
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Oncoimmunology|October 27, 2023
CD39<sup>+</sup> conventional CD4<sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockadeSabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Cell Reports|November 16, 2017
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsCéline Chauvin, Amaury Leruste, Arnault Tauziede-Espariat, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|October 27, 2018
IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During <i>Trypanosoma cruzi</i> InfectionJimena Tosello Boari, Cintia L Araujo Furlan, Facundo Fiocca Vernengo, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Journal for Immunotherapy of Cancer|November 19, 2024
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustionAnais Debesset, Caroline Pilon, Sylvain Meunier, et al.
Plos Biology|June 18, 2026
Argonaute 2 drives resistance to immune checkpoint inhibitors in immunorefractory non-small cell lung cancerDario Pasquale Anobile, Layla Barbar, Emile Maucotel, et al.
Oncoimmunology|May 12, 2025
CD8<sup>+</sup> T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevanceCarolina Abrate, Fernando P Canale, Sabrina N Bossio, et al.
Nature Communications|January 29, 2016
The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivationZhi-Yan Han, Wilfrid Richer, Paul Fréneaux, et al.
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Oncoimmunology|October 27, 2023
CD39<sup>+</sup> conventional CD4<sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockadeSabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, et al.
Oncotarget|April 22, 2017
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancersWilfrid Richer, Julien Masliah-Planchon, Nathalie Clement, et al.
Cell Reports|November 16, 2017
High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid TumorsCéline Chauvin, Amaury Leruste, Arnault Tauziede-Espariat, et al.
Pageof 4